Shares in Japan’s Kyowa Hakko Kirin Co Ltd (TYO: 4151) are up nearly 4% following news that the company will proceed next month with its planned US regulatory submission for burosumab, a monoclonal antibody developed with Californian firm Ultragenyx Pharmaceutical (Nasdaq: RARE).
The biologic is being developed to treat X-linked hypophosphatemia (XLH) and Tumor-induced osteomalacia (TIO), rare diseases connected with excess activity of the hormonal growth factor FGF23.
The companies announced positive Phase III data in XLH in April.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze